Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?
作者信息
Alonso Daniel F, Farina Hernán G
机构信息
Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina.
Laboratory of Molecular Oncology, Department of Science and Technology, National University of Quilmes, Buenos Aires, Argentina.
出版信息
Int J Antimicrob Agents. 2020 Sep;56(3):106125. doi: 10.1016/j.ijantimicag.2020.106125. Epub 2020 Jul 30.
Abstract
摘要
相似文献
1
Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?基于宿主的治疗药物用于治疗2019冠状病毒病（COVID-19）：抗病毒机制与抗癌机制之间的联系？
Int J Antimicrob Agents. 2020 Sep;56(3):106125. doi: 10.1016/j.ijantimicag.2020.106125. Epub 2020 Jul 30.
2
Is the type of diabetes treatment relevant to outcome of COVID-19?糖尿病治疗类型与新型冠状病毒肺炎的预后有关吗？
J Diabetes. 2020 Jul;12(7):486-487. doi: 10.1111/1753-0407.13047.
3
COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.新型冠状病毒肺炎、肺肥大细胞、细胞因子风暴以及木犀草素的有益作用
Biofactors. 2020 May;46(3):306-308. doi: 10.1002/biof.1633. Epub 2020 Apr 27.
4
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
5
Rapid repurposing of drugs for COVID-19.用于治疗新冠肺炎的药物快速重新利用。
Science. 2020 May 22;368(6493):829-830. doi: 10.1126/science.abb9332. Epub 2020 May 8.
6
Drug targets for COVID-19 therapeutics: Ongoing global efforts.抗新冠病毒药物靶点：全球努力持续进行中。
J Biosci. 2020;45(1). doi: 10.1007/s12038-020-00067-w.
7
Repurposing old drugs as antiviral agents for coronaviruses.将老药重新用作冠状病毒的抗病毒药物。
Biomed J. 2020 Aug;43(4):368-374. doi: 10.1016/j.bj.2020.05.003. Epub 2020 May 23.
8
Surviving COVID-19: A disease tolerance perspective.从疾病耐受性角度看新冠病毒感染后的生存情况
Sci Adv. 2020 Apr 29;6(18):eabc1518. doi: 10.1126/sciadv.abc1518. eCollection 2020 May.
9
α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.α-葡萄糖苷酶抑制剂作为具有治疗 COVID-19 潜力的宿主定向抗病毒药物。
Biochem Soc Trans. 2020 Jun 30;48(3):1287-1295. doi: 10.1042/BST20200505.
10
Using "old" medications to fight new COVID-19: Re-purposing with a purpose.使用“旧”药物对抗新型冠状病毒肺炎：有目的地重新利用
J Mol Cell Cardiol. 2020 Sep;146:41-42. doi: 10.1016/j.yjmcc.2020.07.005. Epub 2020 Jul 18.
引用本文的文献
1
Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients.伊维菌素和阿托伐他汀对 SARS-CoV-2 阳性患者鼻咽拭子中宿主细胞内 Importin Alpha 核定位及药物靶标表达谱的影响。
Viruses. 2021 Oct 15;13(10):2084. doi: 10.3390/v13102084.
2
Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial.大剂量伊维菌素对成人新冠病毒肺炎的抗病毒作用：一项概念验证性随机试验。
EClinicalMedicine. 2021 Jun 18;37:100959. doi: 10.1016/j.eclinm.2021.100959. eCollection 2021 Jul.
3
A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19.硝唑尼特在 COVID-19 再利用方面可能的作用机制的综述。
Eur J Pharmacol. 2021 Jan 15;891:173748. doi: 10.1016/j.ejphar.2020.173748. Epub 2020 Nov 20.
本文引用的文献
1
The renin-angiotensin system - a therapeutic target in COVID-19?肾素-血管紧张素系统 - COVID-19 的治疗靶点？
Clin Med (Lond). 2020 Jul;20(4):e72-e75. doi: 10.7861/clinmed.2020-0146. Epub 2020 May 15.
2
Cell entry mechanisms of SARS-CoV-2.SARS-CoV-2 的细胞进入机制。
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734. doi: 10.1073/pnas.2003138117. Epub 2020 May 6.
3
Anticancer mechanisms of metformin: A review of the current evidence.二甲双胍的抗癌机制：现有证据的综述。
Life Sci. 2020 Aug 1;254:117717. doi: 10.1016/j.lfs.2020.117717. Epub 2020 Apr 25.
4
Combination of an Autophagy Inducer and an Autophagy Inhibitor: A Smarter Strategy Emerging in Cancer Therapy.自噬诱导剂与自噬抑制剂的联合使用：癌症治疗中一种新兴的更明智策略。
Front Pharmacol. 2020 Apr 8;11:408. doi: 10.3389/fphar.2020.00408. eCollection 2020.
5
Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells.饥饿和抗代谢疗法促进细胞因子释放和免疫细胞募集。
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9932-9941. doi: 10.1073/pnas.1913707117. Epub 2020 Apr 20.
6
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.药物重定位是治疗冠状病毒 COVID-19 的一种替代方法。
Int J Antimicrob Agents. 2020 Jun;55(6):105969. doi: 10.1016/j.ijantimicag.2020.105969. Epub 2020 Apr 9.
7
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
8
Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.藏而不露：治疗重症 COVID-19 感染患者的方法。
mBio. 2020 Mar 20;11(2):e00398-20. doi: 10.1128/mBio.00398-20.
9
Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin.了解伊维菌素抗肿瘤作用分子机制的进展
Drug Des Devel Ther. 2020 Jan 21;14:285-296. doi: 10.2147/DDDT.S237393. eCollection 2020.
10
Repurposing host-based therapeutics to control coronavirus and influenza virus.基于宿主的治疗药物的再利用以控制冠状病毒和流感病毒。
Drug Discov Today. 2019 Mar;24(3):726-736. doi: 10.1016/j.drudis.2019.01.018. Epub 2019 Jan 31.
Zotero 插件